FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
UroGen Pharma Ltd. - Ordinary Shares
(NQ:
URGN
)
41.40
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about UroGen Pharma Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup
↗
September 05, 2026
Via
Chartmill
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at Upcoming Investor Conferences
September 02, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
August 20, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
August 17, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
Urogen Pharma (NASDAQ:URGN) Nears 52-Week High on Minervini Trend Template and High Growth Momentum Screen
↗
July 09, 2026
Via
Chartmill
UROGEN PHARMA LTD (NASDAQ:URGN) Flawlessly Passes Minervini Trend Template with Accelerating Growth
↗
June 08, 2026
Via
Chartmill
UroGen (URGN) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
ZUSDURI revenue hit $50.4M, growing 73% QoQ as adoption expands into community practices.
Via
The Motley Fool
Topics
Earnings
Intellectual Property
Urogen Pharma Q2 Earnings Call Highlights
↗
August 05, 2026
Urogen Pharma (NASDAQ:URGN) reported second-quarter 2026 revenue of $72.5 million, up from $24.2 million a year earlier, as the commercial launch of bladder cancer treatment ZUSDURI continued to gain...
Via
MarketBeat
Topics
Earnings
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
August 05, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma (NASDAQ:URGN) Crushes Q1 Estimates as ZUSDURI Momentum Accelerates
↗
May 06, 2026
Via
Chartmill
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
July 29, 2026
Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
July 15, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
↗
July 12, 2026
Mark Schoenberg's final disposition under a pre-established Rule 10b5-1 plan follows 191% annual returns, leaving him with 119,763 shares worth $4.82 million.
Via
The Motley Fool
Topics
Regulatory Compliance
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
July 08, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?
↗
June 30, 2026
Focused on innovative cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
↗
June 14, 2026
Focused on urinary tract cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
June 02, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
June 01, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
↗
May 23, 2026
This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
↗
May 23, 2026
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.
Via
The Motley Fool
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
May 15, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
May 13, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen (URGN) Q1 2026 Earnings Transcript
↗
May 07, 2026
UroGen (URGN) Q1 2026 Earnings Transcript
Via
The Motley Fool
UroGen Pharma to Present at Upcoming Investor Conferences
May 07, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
May 06, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
April 29, 2026
Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET
From
UroGen Pharma Ltd.
Via
GlobeNewswire
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
March 30, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?
↗
March 23, 2026
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
